Injections Against HIV Could Be Manufactured Locally and Cheaply, Says Aspen Pharmacare

Cabotegravir is still unaffordable after two years
In 2020, pharmaceutical company ViiV Healthcare announced that a bimonthly injection of its new drug, cabotegravir, prevents HIV infection. More than... | December 1, 2022

Related Keywords

South Africa ,Montreal ,Quebec ,Canada ,United States ,United Kingdom ,Kwazulu ,Eastern Cape ,Natal ,America ,South African ,Aspen Pharmacare ,Francois Venter ,Andy Gray ,Juliet Houghton ,Stavros Nicolaou ,Andrew Hill ,Yogan Pillay ,University Of Kwazulu ,Clinton Health Access Initiative ,African Health Products Regulatory Authority ,Department Of Pharmacology ,News Service English ,Doctors Without Borders ,University Of Liverpool ,World Health Organisation ,Clinicians Society ,Pre Exposure Prophylaxis ,Health Organisation ,Health Access Initiative ,Without Borders ,Sans Fronti ,Patent Pool ,Sub Saharan Africa ,Allafrica Global Media ,Aspen Pharmacare Holdings Limited Stock Exchange ,News ,Information ,Press Release ,Cabotegravir ,Us ,Still ,Unaffordable ,After ,Two ,Harmaceutical ,Company ,Lviiv ,Healthcare ,Nnounced ,Hat ,Bimonthly ,Injection ,F ,Its ,Few ,Prevents ,Shiv ,Ore Apn Zae000066692 ,